Importance of Clinical Trials Participation

Only about 5% of women with a gynecologic cancer participate in the dozens of clinical trials in gynecologic cancers. The predominant hope for improving on the treatment options for women diagnosed with a gynecologic cancer is through the conduct of clinical trials.

The Foundation for Women’s Cancer actively works with the Gynecologic Oncology Group (GOG) to encourage women to participate in clinical trials. Clinical trials are a crucial step in finding new and improved ways to improve treatment for women diagnosed with a gynecologic cancer.

Three examples of the important advances in the care of women as a result of clinical trials include:

  • Chemotherapy added to radiation improve cure rate in locally advanced cervical cancer (GOG 120, 109)
  • Platinum based chemotherapy plus paclitaxel is superior to platinum based chemotherapy plus cyclophosphamide (GOG 111)
  • IP therapy improves survival in subsets of women with newly diagnosed advanced ovarian cancer (GOG 172)

The patients that participated in the phase III clinical trials that led to these discoveries were among the first to benefit from these scientific advancements.

Spotlight

Hear from Dr. Anil Sood, the Foundation’s Research Chairman, and Carol Brown, 2014 SGO Program Chair, about research of interest to women and the public presented at the 2014 SGO Annual Meeting on Women’s Cancer. Watch the video

Awareness

A new SGO Clinical Practice Statement states women diagnosed with epithelial ovarian, tubal, and peritoneal cancers should be considered for genetic counseling and testing, even in the absence of a family history.

Education

The next Gynecologic Cancer Survivors Course Friday, May 2, 2014 in Long Island, NY. For more information on courses, click here.